Experience with intravenous enoxaparin in critically ill infants and children

Pediatric Critical Care Medicine

Volumn 9, Issue 6, 2008, Pages 647-649

  Crary, Shelley E ^a,d   Van Orden, Heidi ^b,c,d   Journeycake, Janna M ^a,d  

^a Department of Pediatrics ^*  (United States)

^b UNIVERSITY OF TEXAS AT DALLAS   (United States)

^c Pharmacy Department

^d The Jane and John Justin Neuroscience Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; BLOOD CLOTTING FACTOR 10A; CREATININE; ENOXAPARIN; PROTEIN ANTIBODY; ANTICOAGULANT AGENT;

ALBUMIN BLOOD LEVEL; ANTICOAGULANT THERAPY; ARTICLE; CHILD; CREATININE BLOOD LEVEL; CRITICALLY ILL PATIENT; HOSPITAL PHARMACY; HUMAN; INFANT; INTENSIVE CARE UNIT; MEDICAL RECORD REVIEW; NEWBORN; PEDIATRIC HOSPITAL; PRESCHOOL CHILD; PRIORITY JOURNAL; RETROSPECTIVE STUDY; THROMBOSIS; THROMBOSIS PREVENTION; TREATMENT DURATION; UNITED STATES; CRITICAL ILLNESS; INTRAVENOUS DRUG ADMINISTRATION; MEDICAL AUDIT;

ANTICOAGULANTS; CHILD; CHILD, PRESCHOOL; CRITICAL ILLNESS; ENOXAPARIN; HUMANS; INFANT; INFANT, NEWBORN; INFUSIONS, INTRAVENOUS; MEDICAL AUDIT; RETROSPECTIVE STUDIES;

EID: 60549102470     PISSN: 15297535     EISSN: None     Source Type: Journal    
DOI: 10.1097/PCC.0b013e31818d1920     Document Type: Article

References (20)

1. Monagle P, Chan A, Massicotte P, et al: An-tithrombotic therapy in children: The seventh ACCP conference on antithrombotic and thrombolytic therapy. Chest 2004; 126: 645S- 687S.
2. Haas CE, Nelsen JL, Raghavendran K, et al: Pharmacokinetics and pharmacodynamics of enoxaparin in multiple trauma patients. J Trauma 2005; 59:1336-1343
3. Ariza-Andraca CR, Altamirano-Bustamante E, Frati-Munari AC, et al: Delayed insulin absorption due to subcutaneous edema. Arch Invest Med (Mex) 1991; 22:229-233
4. Dorffler-Melly J, de Jonge E, Pont AC, et al: Bioavailability of subcutaneous low-molecular-weight heparin to patients on vasopres-sors. Lancet 2002; 359:849-850
5. Priglinger U, Delle Karth G, Geppert A, et al: Prophylactic anticoagulation with enoxapa-rin: Is the subcutaneous route appropriate in the critically ill? Crit Care Med 2003; 31: 1405-1409
6. Krishnan V, Murray P: Pharmacologic issues in the critically ill. Clin Chest Med 2003; 24:671-688
7. Dunaway KK, Gal P, Ransom JL: Use of enox-aparin in a preterm infant. Ann Pharmaco-ther 2000; 34:1410-1413
8. Manco-Johnson MJ, Knapp-Clevenger R: Successful antithrombotic therapy employing intravenous bolus low molecular weight heparin in an extremely premature infant. Abstr 1621. Pediatr Res 2003; 53:284
9. Massicotte MP: Low-molecular-weight hepa-rin therapy in children. J Pediatr Hematol Oncol 2000; 22:98-99
10. Sanchez-Pena P, Hulot JS, Urien S, et al: Anti-factor Xa kinetics after intravenous enoxaparin in patients undergoing percutaneous coronary intervention: A population model analysis. Br J Clin Pharmacol 2005; 60:364-373
11. Massicotte P, Adams M, Marzinotto V, et al: Low-molecular-weight heparin in pediatric patients with thrombotic disease: A dose finding study. J Pediatr 1996; 128:313-318
12. Antman EM, McCabe CH, Gurfinkel EP, et al: Enoxaparin prevents death and cardiac isch-emic events in unstable angina/non-Q-wave myocardial infarction. Results of the throm-bolysis in myocardial infarction (TIMI) 11B trial. Circulation 1999; 100:1593-1601
13. Aslam MS, Sundberg S, Sabri MN, et al: Pharmacokinetics of intravenous/subcutaneous Enoxaparin in patients with acute coronary syndrome undergoing percutaneous coronary interventions. Catheter Cardiovasc Interv 2002; 57:187-190
14. Bijsterveld NR, Moons AH, Meijers JC, et al: The impact on coagulation of an intravenous loading dose in addition to a subcutaneous regimen of low-molecular-weight heparin in the initial treatment of acute coronary syndromes. J Am Coll Cardiol 2003; 42:424-427
15. Chen WH, Lau CP, Lau YK, et al: Stable and optimal anticoagulation is achieved with a single dose of intravenous enoxaparin in patients undergoing percutaneous coronary intervention. J Invasive Cardiol 2002; 14: 439-442
16. Martin JL, Fry ET, Sanderink GJ, et al: Reliable anticoagulation with enoxaparin in patients undergoing percutaneous coronary intervention: The pharmacokinetics of enoxaparin in PCI (PEPCI) study. Catheter Cardiovasc Interv 2004; 61:163-170
17. Le Liboux A, Sanderink GJ, Grosjean P, et al: Enoxaparin pharmacokinetics and pharma-codynamics after intravenous bolus administration alone and at initiation of a subcutaneous doing regimen. J Am Coll Cardiol 2000; 35:373A-374A
18. Lovenox [package insert]. Bridgewater, NJ, Aventis Pharmaceuticals, Inc., 2005
19. Feng Y, Green B, Duffull SB, et al: Development of a dosage strategy in patients receiving enoxaparin by continuous intravenous infusion using modeling and simulation. Br J Clin Pharmacol 2006; 62:165-176
20. Kane-Gill SL, Feng Y, Bobek MB, et al: Administration of enoxaparin by continuous infusion in a naturalistic setting: Analysis of renal function and safety. J Clin Pharm Ther 2005; 30:207-213